|
Indianapolis, Ind. March 8, 2004
Roche Diagnostics Awarded Blood Gas Contract by Novation®
Roche Diagnostics Corporation announced today that the company
has signed a three-year contract with Novation, the supply company
of VHA, Inc. and University HealthSystem Consortium (UHC), to make
available blood gas analyzers, reagents, and consumables to the
more than 2,300 VHA and UHC hospitals and health care facilities
served by Novation. The new agreement also extends to health care
organizations that purchase supplies through HealthCare Purchasing
Partners International . The contract is valued at a potential $17
million per year.
In addition to the blood gas award, which includes the OMNI MODULAR
and Roche OMNI® C Analyzers and DataCare™ IT solution,
Roche Diagnostics is currently under contract with Novation for
blood glucose monitoring, chemistry and immunochemistry products.
This enables VHA, UHC and HPPI members to draw upon Roche Diagnostics'
broad portfolio of total laboratory solutions in their quest to
increase laboratory efficiency while enhancing services to their
physicians with timely and actionable information for patient management.
"We are delighted to have the opportunity to expand our partnership
with Novation and broaden our contract portfolio to VHA, UHC and
HPPI members," said Dick Aderman, senior vice president and
general manager, Roche Centralized and Molecular Diagnostics.
"Roche was awarded this dual-source contract based on input
from member surveys and the Novation Respiratory Council, made up
of member clinicians and purchasing executives," said Larry
Dooley, vice president, Contract and Program Services, for Novation.
"Their decision measured both financial and non-financial criteria,
such as performance, quality and response time."
Blood gas testing is key to today's clinical laboratories and provides
important information on patient status based on the balance of
oxygen and carbon dioxide gases in the blood. This information may
be used in respiratory, metabolic or kidney disorders.
Based in Irving, Tex., Novation was established in January 1998
through a combination of the supply programs of VHA and UHC, two
national health care alliances. Novation serves the purchasing needs
of more than 2,300 members and affiliates of VHA and UHC. In 2003,
VHA and UHC members purchased more than $23 billion in supplies
through Novation contracts.
About Roche and Roche Diagnostics
Headquartered in Basel, Switzerland, Roche is one of the world's
leading innovation-driven healthcare groups. Its core businesses
are pharmaceuticals and diagnostics. Roche is number one in the
global diagnostics market, the leading supplier of pharmaceuticals
for cancer and a leader in virology and transplantation. As a supplier
of products and services for the prevention, diagnosis and treatment
of disease, the Group contributes on a broad range of fronts to
improving people's health and quality of life. Roche employs approximately
65,000 people in 150 countries. The Group has alliances and research
and development agreements with numerous partners, including majority
ownership interests in Genentech and Chugai. Roche's Diagnostics
Division, the world leader in in-vitro diagnostics with a uniquely
broad product portfolio, supplies a wide array of innovative testing
products and services to researchers, physicians, patients, hospitals
and laboratories world-wide. Roche Diagnostics' North American headquarters
are in Indianapolis, Indiana (www.roche-diagnostics.us).
For further information, please visit our websites www.roche.us
and www.roche-diagnostics.com.
For additional information contact:
MODULAR, ROCHE OMNI, and DATACARE are trademarks of a Member of
the Roche Group. All other trademarks are the prop
|
